ALS is a fatal neurodegenerative condition that affects chewing, talking, and walking, progresses to paralysis, and culminates in respiratory failure, typically within three to five years. An estimated 30,000 Americans live with ALS, sometimes called Lou Gehrig’s disease. On Sept. 29, the Food and Drug Administration approved Relyvrio from Amylyx Pharmaceuticals. It’s the first ALS medication to be approved in five years and only one of three currently prescribed to patients to slow the progression of the disease, but should it have been approved?

Sometimes things happen that are beyond human decency. When these things happen and it causes others to lose their lives, we must learn to act to punish those responsible and ensure it never happens again. For more than two years, the Select Subcommittee on the Coronavirus Crisis has been investigating the federal government’s response to the coronavirus pandemic to ensure the American people receive a full accounting of what went wrong and to determine what corrective steps are necessary to ensure our nation is better prepared for any future public health crisis.

Researchers aimed to test the feasibility of a DTx program for patients with cancer, as measured by engagement, retention, and acceptability. In addition, we explored the effects of the program on cancer-related QoL. The high retention, employment, and acceptability found in this study demonstrated that multidisciplinary DTx is feasible for patients with cancer.

When rationalizing their lofty price tags, one of the most common reasons pharma companies cite is that a high price is needed to make good on the money invested in research and development. According to a study, the amount of money spent on research and development (R&D) for new pharmaceutical drugs doesn’t correlate with high prices for the medications.